Gilead Places Partial Clinical Hold on KITE-753 Trials
The company paused two clinical trials to investigate safety data after observing neurotoxicity concerns.
Updated on Oct. 30, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies to prioritize patient safety over accelerating new drug clinical trials?
Gilead Sciences has placed a partial clinical hold on its phase 2 PALISADES-1 and phase 3 PALISADES-2 trials for the cell therapy KITE-753. This action follows an initial voluntary pause by the company to examine safety differences observed between phase 1 and phase 2 data.
Why it matters
The move aims to investigate grade 3 and grade 4 immune effector cell-associated neurotoxicity syndrome, or ICANS, which appeared in more recent trial stages. Gilead is working in alignment with the FDA to ensure participant safety while reviewing the drug's profile.
The investigation centers on grade 3 and grade 4 immune effector cell-associated neurotoxicity syndrome. There have been no reported cases of death or grade 5 adverse events linked to the therapy.
The players
Gilead Sciences
A research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need.
Kite Pharma
A subsidiary of Gilead Sciences focused on the development of innovative cancer immunotherapies, specifically CAR-T cell therapy.
FDA
The federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
The details
Gilead Sciences initiated the review after identifying safety discrepancies during the PALISADES-1 and PALISADES-2 studies. The company is actively collaborating with federal regulators to evaluate the severity of the neurological side effects identified during these trials.
Timeline
Gilead acquired Kite Pharma for $11.9 billion in 2017.
Kite revealed phase 1 data for KITE-753 in late 2025.
Johnson & Johnson exited the CAR-T race in May 2026.
Gilead reported its third-quarter financial earnings in Q3 2026.
The partial clinical hold was announced on October 29, 2026.
The Tech Race
This clinical hold follows the standard regulatory pattern where a sponsor pauses development to address emerging safety signals in compliance with agency oversight. It highlights the inherent risks in evolving cell therapy platforms as companies compete for dominance in oncology.
The clinical hold does not directly impact current commercial products but reflects the volatility of the company's research-heavy pipeline. Investors and patients should monitor updates as the company clarifies the future path for these specific experimental therapies.
The takeaway
Maintaining rigorous safety standards is a critical component of the biopharmaceutical development process. Companies often balance aggressive expansion of therapy pipelines with the necessity of addressing adverse medical events as they emerge in late-stage trials.
Further reading
For more on industry updates, visit the Biotech section.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.
Live Poll
Do you trust pharmaceutical companies to prioritize patient safety over accelerating new drug clinical trials?
